-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Narmafotinib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Narmafotinib in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Narmafotinib in Pancreatic Cancer Drug Details: AMP-945 (CTX-0294945) is under investigation for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sodium Benzoate in Schizophrenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sodium Benzoate in Schizophrenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sodium Benzoate in Schizophrenia Drug Details: Sodium benzoate (SND-1, SB-01, SR-01) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Narmafotinib in Squamous Cell Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Narmafotinib in Squamous Cell Carcinoma Drug Details: AMP-945 (CTX-0294945) is under investigation for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Narmafotinib in Metastatic Adenocarcinoma of The Pancreas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Narmafotinib in Metastatic Adenocarcinoma of The Pancreas Drug Details: AMP-945 (CTX-0294945) is under investigation for...
-
Product Insights
Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRGN-2009 in Human Papillomavirus (HPV) Associated Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRGN-2009 in Human Papillomavirus (HPV) Associated Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRGN-2009 in Human Papillomavirus (HPV) Associated Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Alrizomadlin in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Alrizomadlin in Relapsed Acute Myeloid Leukemia Drug Details: Alrizomadlin (APG-115) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emavusertib Hydrochloride in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emavusertib Hydrochloride in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Emavusertib Hydrochloride in Marginal Zone B-cell Lymphoma Drug Details:Emavusertib hydrochloride...